Page 103 - Read Online

Sanal et al. Metab Target Organ Damage 2024;4:45 https://dx.doi.org/10.20517/mtod.2024.54 Page 11 of 11

Clin Gastroenterol Hepatol 2024;22:1275-85.e2. DOI PubMed
23. Liu CJ, Seto WK, Yu ML. Dual-etiology MAFLD: the interactions between viral hepatitis B, viral hepatitis C, alcohol, and MAFLD.
Hepatol Int 2024;18:897-908. DOI PubMed
24. Lima-Cabello E, García-Mediavilla MV, Miquilena-Colina ME, et al. Enhanced expression of pro-inflammatory mediators and liver
X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C. Clin Sci 2011;120:239-50. DOI PubMed
25. Ciardullo S, Perseghin G. From NAFLD to MAFLD and MASLD: a tale of alcohol, stigma and metabolic dysfunction. Metab Target
Organ Damage 2024;4:30. DOI
26. Machado MV. What should we advise MAFLD patients to eat and drink? Metab Target Organ Damage 2021;1:9. DOI
27. Lai J, Wang HL, Zhang X, Wang H, Liu X. Pathologic diagnosis of nonalcoholic fatty liver disease. Arch Pathol Lab Med
2022;146:940-6. DOI PubMed
28. Zhao Q, Deng Y. Comparison of mortality outcomes in individuals with MASLD and/or MAFLD. J Hepatol 2024;80:e62-4. DOI
PubMed
29. Alboraie M, Butt AS, Piscoya A, et al. Why MASLD lags behind MAFLD: a critical analysis of diagnostic criteria evolution in
metabolic dysfunction-associated liver diseases. Med Sci Monit 2024;30:e945198. DOI PubMed PMC
30. Pan Z, Derbala M, AlNaamani K, Ghazinian H, Fan JG, Eslam M. MAFLD criteria are better than MASLD criteria at predicting the
risk of chronic kidney disease. Ann Hepatol 2024;29:101512. DOI PubMed
31. Pan Z, Al-Busafi SA, Abdulla M, Fouad Y, Sebastiani G, Eslam M. MAFLD identifies patients with significant hepatic fibrosis better
than MASLD. Hepatol Int 2024;18:964-72. DOI PubMed
32. Eslam M, Alkhouri N, Vajro P, et al. Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert
consensus statement. Lancet Gastroenterol Hepatol 2021;6:864-73. DOI PubMed